Scroll for more

blog

Apr 4, 2018 benevolentai

RESEARCH | Organic synthesis provides opportunities to transform drug discovery

Ian Churcher, VP Drug Discovery recently published a paper in Nature to highlight how organic synthesis could represent an opportunity for the pharmaceuticals industries to improve drug development. He presents the current challenges that the industry needs overcome and explains how new technologies and industry-academia collaborations are essential to progress.

Apr 3, 2018 benevolentai

Love drug discovery? You just need the right chemistry!

There is an increasing number of varieties of drug agents in clinical use ranging from antibodies and proteins to nucleic acids and, increasingly, cellular and genetic therapies but the majority of drugs on the market and in development today are still small, synthetic molecules made in a chemistry laboratory.

Mar 29, 2018 benevolentai

RESEARCH | Planning chemical syntheses with deep neural networks and symbolic AI

Marwin Segler, senior machine learning researcher at BenevolentAI, shows in his Nature paper how AI can transform the success rate of planning the synthesis of organic molecules – so-called retrosynthesis.